KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $8.8 million.

  • Neogenomics' Depreciation and Depletion fell 1082.73% to $8.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $36.1 million, marking a year-over-year decrease of 774.66%. This contributed to the annual value of $36.1 million for FY2025, which is 774.66% down from last year.
  • Neogenomics' Depreciation and Depletion amounted to $8.8 million in Q4 2025, which was down 1082.73% from $8.8 million recorded in Q3 2025.
  • Over the past 5 years, Neogenomics' Depreciation and Depletion peaked at $9.9 million during Q1 2024, and registered a low of $6.7 million during Q1 2021.
  • For the 5-year period, Neogenomics' Depreciation and Depletion averaged around $8.9 million, with its median value being $9.1 million (2023).
  • Per our database at Business Quant, Neogenomics' Depreciation and Depletion soared by 2567.37% in 2022 and then tumbled by 1082.73% in 2025.
  • Neogenomics' Depreciation and Depletion (Quarter) stood at $8.4 million in 2021, then rose by 13.04% to $9.5 million in 2022, then increased by 1.06% to $9.6 million in 2023, then grew by 2.6% to $9.8 million in 2024, then fell by 10.83% to $8.8 million in 2025.
  • Its Depreciation and Depletion stands at $8.8 million for Q4 2025, versus $8.8 million for Q3 2025 and $9.1 million for Q2 2025.